In the CodeBreaK 300 trial, sotorasib and panitumumab had better response rates and improved PFS vs standard-of-care ...
Future data on overall survival will be beneficial for prescribing the treatment to patients after the approval. 1. FDA approves sotorasib with panitumumab for KRAS G12C-mutated colorectal cancer.
The Discovery of Sotorasib (AMG 510): First-in-Class Investigational Covalent Inhibitor of KRAS G12C
Join Brian Lanman of Amgen as he outlines the strategies used to overcome these challenges, the screening approaches employed to identify starting points for these efforts, and the optimization ...
As previously reported, the doublet combination of avutometinib with sotorasib has completed enrollment in the G12C inhibitor treatment-naive Stage 1 Part B cohort. The KRAS G12C inhibitor prior ...
As previously reported, the doublet combination of avutometinib with sotorasib has completed enrollment (n=28) in the G12C inhibitor treatment-naïve Stage 1 Part B cohort. The KRAS G12C ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback